Dysarthria as Late Effect of Stroke Clinical Trial
Official title:
A Prospective, Randomized, Multi-Centered Clinical Trial to Investigate the Effectiveness of Smartphone-Based Speech Therapy for People With Post-Stroke Dysarthria
Verified date | May 2023 |
Source | Ewha Womans University Seoul Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial aims to determine if a new smartphone-based speech therapy is effective self-treatment method for patients with post-stroke dysarthria. For this study, participants in the intervention group will use the speech therapy app for 1 hour per day, 5 days per week, over a 4-week period. The active control group will receive home-based speech therapy with the same duration and frequency as the intervention group. The study will help us understand if smartphone-based speech therapy is a viable treatment option for post-stroke dysarthria patients.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | May 2024 |
Est. primary completion date | April 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Aged 18 or over. 2. Neurologically stable stroke patients diagnosed by a stroke specialist neurologist. 3. Diagnosis of dysarthria caused by stroke as confirmed by a stroke specialty neurologist. 4. First-ever stroke patients without previous stroke history. 5. Patients with sufficient cognitive abilities to operate the smartphone-based speech therapy application (Mini-Mental State Exam score = 26) 6. As judged by the neurology specialists: patients with sufficient vision, hearing, communication skills, and motor skills to participate in this study 7. Must have voluntarily understood the trial and signed a consent form agreeing to comply with precautions. Exclusion Criteria: 1. Co-existing language disorder (e.g., aphasia). Aphasia will be determined by a stroke specialist. 2. Co-existing progressive neurological disorders that can affect dysarthria (e.g., dementia, Pick's disease, Huntington's disease, Parkinson's disease, or Parkinsonism). 3. Diagnosis of severe mental disorders as determined by a clinician (e.g., depression, schizophrenia, alcohol addiction, or drug addiction). 4. Patients taking concomitant medications that could affect the trial results during the study period (e.g., cognitive dysfunction medications, anticholinergics, anti-epileptic drugs, anti-anxiety drugs, antidepressants, antipsychotics, and hypnotics). 5. Patients unable to use/access smartphone technology. 6. Illiterate patients. 7. Patients unable to communicate in Korean. 8. Is unsuitable for participation due to other reasons, as determined by the investigator. 9. Has refused to participate in the study. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Ewha Womans University Seoul Hospital | Ewha Womans University Mokdong Hospital, National Rehabilitation Center, Seoul, Korea |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Patient Health Questionnaire-9 (PHQ-9) | PHQ-9 will be used to assess depression. The PHQ-9 is a nine-item self-reported questionnaire for the measurement of depressive symptoms during the last two weeks. | Baseline, 4 weeks | |
Other | Quality of Life in the Dysarthric Speaker (QOL-Dys) | QOL-Dys will be used to assess the comprehensive quality of life of individuals with dysarthria. The questionnaire consists of four dimensions: characteristics of speech, situational difficulties, use of compensation strategies, and perception of others. The responses are rated on a 5-point scale from 0 to 4, indicating the extent to which participants agree with each statement. | Baseline, 4 weeks | |
Other | Communicative Effectiveness Survey (CES) | CES will be used to assess the communication efficiency of individuals with dysarthria in daily situations. The rating scale consists of 8 items and uses a 7-category rating scale ranging from "1 = not effective at all" to "7 = extremely effective" for everyday speaking situations. | Baseline, 4 weeks | |
Other | System Usability Questionnaire (SUS) | SUS will be used to assess user's subjective views of a system's usability. SUS will only be used in the intervention group at the end of treatment. | 4 weeks | |
Other | Application usage logs | The log data will be used to evaluate compliance and acoustic factors. During the 4-week experimental period, the application login time, daily task completion rate, and raw data (.wav) of patients' voices are stored on the server for analysis. | 4 weeks | |
Primary | Speech intelligibility | The change in speech intelligibility from baseline to 4 weeks post-intervention will be assessed. Speech intelligibility will be evaluated by having three naive listeners transcribe the participants' recorded speech. These transcriptions will then be compared to the original sentences to calculate a percentage score representing intelligibility. The final intelligibility score will be calculated as the average of the scores from the three naive listeners. A higher percentage indicates greater speech intelligibility. | Baseline, 4 weeks | |
Secondary | Maximum phonation Time (MPT) | The change in maximum phonation time (MPT) from baseline to 4 weeks post-intervention will be assessed. MPT will be used to assess participants' maximum phonation time. The speech evaluator instructs the patient to take a comfortable breath and then produce the sound /a/ for as long as possible. The task is performed twice, and the maximum duration of the two measurements is used. | Baseline, 4 weeks | |
Secondary | Oral-diadochokinesis (DDK) | The Oral-diadochokinesis (DDK) change from baseline to 4 weeks post-intervention will be assessed. DDK will be used to assess articulation rate, regularity, and accuracy. Participants are instructed to repeat the syllables /pa/, /ta/, /ka/, and /pataka/ as quickly and accurately as possible. The number of repetitions is divided by the duration of the task. | Baseline, 4 weeks | |
Secondary | Percentage of Consonants Correct (PCC, %) | The Percentage of Consonants Correct (PCC, %) change from baseline to 4 weeks post-intervention will be assessed. PCC is evaluated as a percentage score calculated from the Urimal Test of Articulation and Phonology 2 (UTAP2). | Baseline, 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05865106 -
The Efficacy and Feasibility of Smartphone-Based Speech Therapy for People With Post-Stroke Dysarthria
|
N/A | |
Completed |
NCT05146765 -
Efficacy of a Digital Therapeutic for People With Dysarthria After Stroke
|
N/A | |
Recruiting |
NCT04427670 -
Implementation & Feasibility Study of Patients With Dysarthria Following Stroke & Their Carers in Pakistan
|
N/A |